The mutant hematopoietic tissues also showed zero expression of both GATA-1 and GATA-2, two important transcription factors whose expression is required during early embryogenesis to regulate genes during development and differentiation of hematopoietic cells. Finally, in a recent paper published in Nature, Stainier and his team were able to finally uncover the gene responsible for the condition of the cloche zebrafish mutant.
They started by examining 26,000 genes from the cloche genome, all of which were cloche suspects. “Identifying cloche was like solving a decades-old criminal case of genetics,” said Sven Reischauer, one of the main authors of the study. “However, in this case, it was not the perpetrator who was unknown but the victim, the defective gene."
17 out of the 26,000 were then targeted as potential defective genes. To pinpoint the true mutant gene out of the lineup, the researchers created several knockout lines for each candidate, introducing them into zebrafish embryos, deactivating them, and then following blood vessel and blood cell growth in each subject to see if the condition matched that of cloche.
With the cloche gene confirmed, researchers now ponder the many clinical applications that might arise from manipulating the expression of the gene. Of all the genes known to be related to blood vessel formation, they are all dependent on whether the cloche gene has been activated. Scientists believe this level of control could greatly contribute to personalized stem cell therapy and so much more.
Sources: Max Planck Gesellschaft, Development, Nature